Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Megestrol Acetate Oral Suspension Nanocrystal Dispersion 115 Mgml

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00637572Phase 2Completed

Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss

NCT00006158Phase 2CompletedPrimary

AIDS Wasting in Women: Anabolic Effects of Testosterone

Showing all 2 trials

Research Network

Common Treatments

  • Megestrol Acetate Oral Suspension Nanocrystal Dispersion 115 Mgml1
  • Testosterone1
  • Megestrol Acetate1

Active Sponsors

  • Endo USA Inc., a Keenova Therapeutics Company1
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1
  • Quintiles, Inc.1

Top Investigators

Related Conditions

  • Cachexia1
  • Anorexia1
  • Hiv Infections1
  • Hiv Wasting Syndrome1

Activity Timeline